Heterodox
Inflation Reduction Act The Inflation Reduction Act drug price negotiation is small in returns, low in the number of drugs initially impacted, and slow to start. Ten drugs will be selected and the impact of the act begins in 2026. It rises to 20 drugs to be negotiated in 2029. The new act ignores European reference pricing and instead caps prices at a set discount of average U.S. prices. The act establishes an initial standard in which the scope...
Read More »Drug price control in the Inflation Reduction Act
